ASCO GU 2025: Darolutamide Monotherapy in Patients with CSPC after Biochemical Recurrence: ARAMON Lead-in Phase Results
The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Xin Gao discussing lead-in phase results of the ARAMON trial assessing darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence.
Read More
ASCO GU 2024: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing Darolutamide vs Enzalutamide Monotherapy on Serum Testosterone Levels in Patients With Castration-Sensitive Prostate Cancer After Biochemical Recurrence
Presented by Andrew Laccetti, MD, MS
(UroToday.com) The 2024 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to a prostate cancer trials in progress poster session. Dr. Andrew Laccetti presented ARAMON, a phase 2, randomized, open-label study comparing darolutamide and enzalutamide monotherapy’s effects on serum testosterone levels in patients with castration-sensitive prostate cancer in the setting of biochemical recurrence.
Read More
ASCO 2023: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients with Hormone-Naive Prostate Cancer
(UroToday.com) The 2023 ASCO annual meeting included a prostate cancer session, featuring a trials in progress presentation by Dr. Xin Gao discussing ARAMON, a phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer.
Read More